AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins(IAP), inhibits progression of human ovarian Y binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, 50- to 100-fold higher affinities than the Smac AVPI peptide.
| Pack Size | Availability | Price/USD | Quantity |
|---|---|---|---|
| 2 mg | 2-3 weeks | $ 96 | |
| 4 mg | 2-3 weeks | $ 172 | |
| 8 mg | 2-3 weeks | $ 240 | |
| 20 mg | 2-3 weeks | $ 529 | |
| 40 mg | 2-3 weeks | $ 841 |
| Description | AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins(IAP), inhibits progression of human ovarian Y binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, 50- to 100-fold higher affinities than the Smac AVPI peptide. |
| Targets&IC50 | cIAP2-BIR3: 5.1 nM(Ki), XIAP-BIR3: 66.4 nM(Ki), cIAP1-BIR3: 1.9 nM(Ki) |
| In vitro | Cells are seeded in 96-well flat bottom cell culture plates at a density of (3-4) × 103 cells/well with AT-406 and incubated for 4 days. The rate of cell growth inhibition after treatment with different concentrations of AT-406 is determined by assaying with (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-8). WST-8 is added to each well to a final concentration of 10%, and then the plates are incubated at 37 °C for 2−3 hours. The absorbance of the samples is measured at 450 nm using a TECAN ULTRA reader. Concentration of AT-406 that inhibited cell growth by 50% (IC50) is calculated by comparing absorbance in the untreated cells and the cells treated with AT-406. (Only for Reference) |
| Synonyms | AT-406 HCl, SM-406 |
| CAS No. | 1071992-57-8 |
| Chemical Formula | C32H44ClN5O4 |
| Molecular Weight | 598.19 |
| Solubility | H2O: <1 mg/mL Ethanol: 100 mg/mL (178.02 mM); DMSO: 100 mg/mL (178.02 mM) |
| Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
In vivo Formulation Calculator (Clear solution)Calculatorbottom
